Peripheral Vascular Disease
📧 Sign up to get email alerts when something new happens for Peripheral Vascular Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-03EMA Authorised: Clopidogrel Zentiva (previously Clopidogrel Winthrop) (clopidogrel) — Zentiva k.s.
Authorisation granted for Clopidogrel Zentiva (clopidogrel), expanding or confirming its availability for stroke, peripheral vascular diseas…
-
EMA approval · 2026-03-31EMA Authorised: Brilique (ticagrelor) — AstraZeneca AB
EMA authorised Brilique (ticagrelor) for use in acute coronary syndrome and peripheral vascular disease, with AstraZeneca AB as the marketin…
-
EMA approval · 2025-12-12EMA Authorised: Clopidogrel Viatris (previously Clopidogrel Taw Pharma) (clopidogrel besilate) — Viatris Limited
The EMA has authorized Clopidogrel Viatris (clopidogrel besilate) for use in preventing thrombotic events in patients with peripheral vascul…
-
EMA approval · 2025-08-26EMA Authorised: Iscover (clopidogrel) — Sanofi Winthrop Industrie
The European Medicines Agency has authorised Iscover, a clopidogrel product from Sanofi Winthrop Industrie, for preventing thrombotic events…
-
EMA approval · 2025-07-14EMA Authorised: Plavix (clopidogrel hydrogen sulfate) — Sanofi Winthrop Industrie
The EMA authorised Plavix (clopidogrel hydrogen sulfate) for use with indications including stroke, peripheral vascular disease, atrial fibr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-06-23EMA Authorised: Grepid (clopidogrel (as besilate)) — Pharmathen S.A.
EMA authorised the drug Grepid, containing clopidogrel besilate, for indications including peripheral vascular diseases, stroke, and myocard…
-
EMA approval · 2025-05-14EMA Authorised: Zyllt (clopidogrel (as hydrogen sulfate)) — Krka, d.d., Novo mesto
EMA authorised Zyllt, a clopidogrel hydrogen sulfate product by Krka, d.d., Novo mesto. It is indicated for preventing vascular events in pa…
-
EMA approval · 2025-05-13EMA Authorised: Clopidogrel Krka d.d. (previously Zopya) (clopidogrel (as hydrochloride)) — Norpharm Regulatory Services Ltd
The EMA authorised Clopidogrel Krka d.d. for indications including peripheral vascular disease, stroke, and myocardial infarction; the marke…
-
EMA approval · 2025-05-13EMA Authorised: Clopidogrel TAD (clopidogrel (as hydrochloride)) — Tad Pharma GmbH
EMA authorised Clopidogrel TAD (clopidogrel hydrochloride) by Tad Pharma GmbH for use in peripheral vascular diseases, stroke, and myocardia…
-
EMA approval · 2024-03-26EMA Authorised: Clopidogrel ratiopharm (clopidogrel (as hydrogen sulfate)) — Teva B.V.
European Medicines Agency authorises Clopidogrel ratiopharm (clopidogrel hydrogen sulfate) for multiple cardiovascular indications including…
-
FDA approval · 2020-11-02FDA Approved: PENTOXIFYLLINE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for pentoxifylline submitted by Rising Pharma Holdings, Inc., indicating an approved change related …